These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17033166)

  • 1. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein.
    Beyeler M; Waldispuhl S; Strobel K; Joller-Jemelka HI; Burg G; Dummer R
    Dermatology; 2006; 213(3):187-91. PubMed ID: 17033166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
    Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
    Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma.
    Bolander A; Agnarsdóttir M; Wagenius G; Strömberg S; Pontén F; Ekman S; Brattström D; Larsson A; Einarsson R; Ullenhag G; Hesselius P; Bergqvist M
    Melanoma Res; 2008 Dec; 18(6):412-9. PubMed ID: 19011512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
    Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
    Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph node metastases--a prospective study in 231 patients.
    Neuss H; Koplin G; Raue W; Reetz C; Mall JW
    Acta Chir Belg; 2011; 111(4):214-8. PubMed ID: 21954736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous melanoma: baseline and ongoing laboratory evaluation.
    Garbe C
    Dermatol Ther; 2005; 18(6):413-21. PubMed ID: 16297017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the determination of serum markers in patients with malignant melanoma.
    Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
    Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
    Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
    Jury CS; McAllister EJ; MacKie RM
    Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma staging: facts and controversies.
    Forschner A; Eigentler TK; Pflugfelder A; Leiter U; Weide B; Held L; Meier F; Garbe C
    Clin Dermatol; 2010; 28(3):275-80. PubMed ID: 20541679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
    Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
    Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
    Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
    Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
    Mian S; Ugurel S; Parkinson E; Schlenzka I; Dryden I; Lancashire L; Ball G; Creaser C; Rees R; Schadendorf D
    J Clin Oncol; 2005 Aug; 23(22):5088-93. PubMed ID: 16051955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of serum S100 protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer].
    Luo RC; He XB; Cai HB; Li AM
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):102-4. PubMed ID: 14724113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
    Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
    Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIA, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
    Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.